Navigation Links
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Advaxis, Inc.
Date:4/28/2008

NEW YORK, April 28 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on Advaxis, Inc. (OTC Bulletin Board: ADXS). The full 60-page report can be found at http://www.crystalra.com.

Advaxis, Inc. ("Advaxis" or "the Company") uses live, genetically modified Listeria monocytogenes ("Listeria") to safely create vaccines that stimulate multiple immune responses against cancer as well as infectious and immune disorders. Through patented techniques, the Company engineers the Listeria bacteria to secrete a specific antigen. The recipients' immune system recognizes and processes that antigen in order to provoke an immune attack against the cancer. Advaxis' Listeria platform technology is licensed from the University of Pennsylvania, where it has been developed over the past 15 years by Dr. Yvonne Paterson, the scientific founder of the Company and current chair of its Scientific Advisory Board.

At present, Advaxis is engineering Listeria to fight cervical intraepithelial neoplasia ("CIN") and cervical, head and neck, prostate, breast, and other cancers. The cancer vaccine market is forecast to reach over $8 billion by 2012, up from $481 million in 2007. In preclinical studies, Listeria-based cancer vaccines have a 100% therapeutic response rate and consistently provoke tumor regression, completely eliminating tumors in over 50% of mice. Moreover, animals dosed with these vaccines show a long-term immunity against cancer, with new tumor cells unable to grow. This suggests that the technology can not only treat existing tumors but may also prevent cancer recurrence.

In 2007, Advaxis completed its first human clinical trial of the Listeria platform using Lovaxin C, a vaccine for human papillomavirus (HPV)-derived cervical cancer. In the Phase I trial, the vaccine has been shown to be safely administered to humans and w
'/>"/>

SOURCE Crystal Research Associates, LLC
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
2. Alara Receives FDA Clearance to Market CRystalView T-Series CR system
3. A New Year, A New Opportunity: Metropolitan Community Church Leaders Urge Faith Leaders to Address HIV and Crystal Meth Use Among LGBT Youth
4. Wellness Experts From Cleveland Clinic Set for 2008 Crystal Voyages
5. Crystal Light and Mandy Moore Launch Unique Online Wellness Community for Women
6. Measurement technique probes surface structure of gold nanocrystals
7. Stanford researchers find culprit in aging muscles that heal poorly
8. Children of depressed moms do better when dad is involved, SLU researcher finds
9. UCLA researchers identify markers that may predict diabetes in still-healthy people
10. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
11. New research shows how chronic stress worsens neurodegenerative disease course

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...avily more often than younger people, study finds,...- Older people who are problem drinkers consume mo...report finds, possibly because they need more alco... a study released this month, people dependent on ... drinks a week, on average. By contrast, younger a...
(Date:11/30/2009).... Rappa, MD, explores the intricate connection bet...ealing Heart to Soul: One Doctor’s Journey o...9). , Dallas, TX (Vocus) ... let go of negative emotions, whether caused by us...oulders. Oftentimes, this disease of the human spi...
(Date:11/30/2009)..., Nov. 30 Baxa Corporation is spon... "culture of safety" means in today,s pharmacy env...eating a Culture of Safety in Pharmacy ," features... their experiences with culture of safety, what it...d the role of technology in enabling or inhibiting...
(Date:11/30/2009)...v. 30 EMD Serono, an affiliate of ...at it received a refuse to file letter from the US...g Application (NDA) for Cladribine Tablets, EMD Se...n of cladribine, as a therapy for relapsing forms ...ll work closely with the FDA to fully understand F...
(Date:11/30/2009)... A new study has found that 27% of...rance customers have a current intention to shop f...he figure is up from 20% in 2008. Over the past f...een a leading indicator of actual switching patter...itch actually will leave their current insurer for...
Breaking Medicine News(10 mins):Health News:Binge Drinking Not Just a Rite of the Young 2Health News:Healing from the Inside Out: Compelling New Book Explores the Intricate Connection between Body, Soul, and Better Health 2Health News:Baxa to Sponsor ASHP Midday Symposium: Creating a Culture of Safety in Pharmacy, A Panel Discussion on Lessons Learned 2Health News:Baxa to Sponsor ASHP Midday Symposium: Creating a Culture of Safety in Pharmacy, A Panel Discussion on Lessons Learned 3Health News:EMD Serono Receives Refuse to File Letter from FDA on Cladribine Tablets New Drug Application 2Health News:EMD Serono Receives Refuse to File Letter from FDA on Cladribine Tablets New Drug Application 3Health News:More Seniors Considering Health Insurance Switch 2
...sparities Show That,"Geography Matters" for U.S. C... Identified as 10 Bottom States by Key Child Well-...ates of,Louisiana and Vermont may be part of the s... is born and raised can,make a shockingly large di...
...ETAIRIE, La., April 2, 2008 OrthoSynetics(TM), th...ntic and dental practices,worldwide, produces tele...s,and practices -- and this year, the production o..., but for the opportunity to work,and contract wit...
...al attention at any,sign of infection, ROCHESTER,...ds that patients who are 50 or older and take mult...y bowel disease have a higher,risk for developing ...or Crohn,s disease, the most common forms of infla...
...tions are associated with increased risk of lung c...eam led by scientists at The University of Texas M... online edition of Nature Genetics. , "This is th... in M. D. Anderson,s Department of Epidemiology. T...
...dents have been indicted in connection with an $11...ion clinics, Assistant Attorney General,Alice S. F.... Alexander,Acosta of the Southern District of Flo...Carmen Gonzalez,33, were all charged today in fede...
...f Upper,Union Street Veterinary Hospital in Schene...mmit VetPharm,s "The Great Vectra 3D(TM)" $125,000...s multi-level contest and,will receive $25,000 in ...m. There will be one more lucky $25,000,winner in ...
Other Medicine News:Health News:Report: 'Life And Death' Differences in U.S. Child Well-Being Exist Between Top and Bottom States, Youths Up to Three Times More Likely to Die Before Adulthood in Some Parts of U.S. 2Health News:Report: 'Life And Death' Differences in U.S. Child Well-Being Exist Between Top and Bottom States, Youths Up to Three Times More Likely to Die Before Adulthood in Some Parts of U.S. 3Health News:Report: 'Life And Death' Differences in U.S. Child Well-Being Exist Between Top and Bottom States, Youths Up to Three Times More Likely to Die Before Adulthood in Some Parts of U.S. 4Health News:Report: 'Life And Death' Differences in U.S. Child Well-Being Exist Between Top and Bottom States, Youths Up to Three Times More Likely to Die Before Adulthood in Some Parts of U.S. 5Health News:OrthoSynetics(TM) Brings Ad Production Home to New Orleans 2Health News:Mayo Clinic Identifies Infection Risks for Patients with Inflammatory Bowel Disease 2Health News:Genetic variations raise lung cancer risk for smokers and ex-smokers 2Health News:Genetic variations raise lung cancer risk for smokers and ex-smokers 3Health News:Genetic variations raise lung cancer risk for smokers and ex-smokers 4Health News:Seven Miami-Area Residents Charged in $11 Million Medicare Fraud Scheme 2Health News:Summit VetPharm Announces Second Winner in Its 'Great Vectra 3D(TM)' $125,000 Giveaway 2
(Date:11/30/2009).... 30 Cytokine PharmaSciences, Inc.... of CPSI-2364, its orally active, small-molecule i...pro-inflammatory cytokines. Results of the safety... volunteers confirm the safety of this compound in... subjects completed the study, including those rec...
(Date:11/30/2009)...PRNewswire/ -- The Simmons law firm,s Trent Miracl...ing thousands of women that were seriously injured...rol pill manufactured and marketed by Bayer Pharma...istrict Litigation has ordered that all federal Ya...idated and centralized for pretrial litigation in ...
(Date:11/30/2009)... 30 According to Millennium Resear...chnology market intelligence, the nearly $1.2 bill...most 5% over 2008 as patients chose to delay or fo... The market will, however, begin recovery in 2010,...ion growth rates of over 15%. MRG,s facial injecta...
Breaking Medicine Technology:Cytokine PharmaSciences Completes Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364 2Simmons Firm's Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer 2Facial Injectables Emerge From the Recession 2Facial Injectables Emerge From the Recession 3Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 1Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 2Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 3Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 4Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 5Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 6Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 7Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 1Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 2Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 3Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 4Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 1Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 2Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 3Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 4
...MELBOURNE, Australia, Feb. 11 Phosphagenics,Limit...PGNY) and Nestle,Nutrition (Nestle) today announce... establish the efficacy of Phosphagenics, Phospha ...vancing at three sites in Adelaide,Australia., Ba...ants, the,double-blind phase 2 trial, which is ful...
...BOULDER, Colo., and MONTREAL, Feb. 11 ,Pharmion (N...y announced that,the European Medicines Agency (EM...CD0103, a histone deacetylase (HDAC) inhibitor, as...acute myelogenous leukemia in the,European Union (...duct be,intended for the treatment of life-threate...
Other Medicine Technology:Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 2Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 3Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 4Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 2Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 3Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 4
Satin-Slip® 10FR Intubating Stylet
Disposable Aluminum 11 1/2" Stylette
Solid Copper Malleable Stylette
S5000N Ultra-Slip™ Stylet
Medicine Products: